First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy
Related Questions
How will the Health Canada approval of Amtagvi® affect IOV's short‑term and near‑term stock price and trading volume?
What is the expected commercial launch timeline in Canada, including pricing, reimbursement and market uptake compared to existing melanoma therapies?
How does this approval position Iovance against competitors in the T‑cell and melanoma space, and what are the implications for its broader pipeline and future regulatory milestones?